Разработка процесса непрерывного культивирования клеток CHO - продуцентов рекомбинантного фактора свертываемости крови VIII
Аннотация
Об авторах
А. Н. МорозовРоссия
Г. Д. Сидельников
Россия
И. М. Емельянов
Россия
К. Е. Лапшин
Россия
Д. Р. Алимова
Россия
Список литературы
1. Fay P.J. Factor VIII structure and function. Int J Hematol. 2006; 83: 103-8.
2. Casademunt E., Martinelle K., Jernberg M., Winge S., Tiemeyer M., Biesert L., et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol. 2012; 89(2): 165-76.
3. Miao H., Sirachainan N., Palmer L., Kucab P., Cunningham M., Kaufman R., Pipe S. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103:3412-9.
4. Kaufman R.J., Wasley L.C., Davies M.V., Wise R.J., Israel D.I., Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in chinese hamster ovary cells. Mol Cell Biol. 1988; 9(3): 1233-42.
5. Adamson R. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Hematol. 1994; 68:9-14.
6. Clincke M., Molleryd C., Zhang Y., Lindskog E., Walsh K., Chotteau V. Very high cell dencity of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell dencity on the process. Biotechnol Prog. 2013; 29(3): 754-67.
7. Santagostino E. A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther. 2014; 8:2507-15.
8. Kaufman R.J. Insight into the structure., function., and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol. 1991; 63(3): 155-65.
9. Ezban M., Vad K., Kjalke M. Turoctocog alfa (NovoEight) - from design to clinical proof of concept. Eur J Haematol. 2014; 93(5): 369-76.
10. Chotteau V., Bjorling T., Boork S., Brink-Nilsson H. Development of a large scale process for the production of recombinant truncated factor VIII in CHO cells under cell growth arrest conditions. In: Lindner-Olsson E. Animal Cell Technology: From Target to Market. Kluwer Academic Publ.; 2001. P. 287-91.
11. Chuppa S., Tsai Y., Yoon S., Shackleford S., Rozales C., Bhat R., et al. Fermentor temperature as a tool for control of high-dencity perfusion cultures of mammalian cells. Biotechnol Bioeng. 1997; 55(2): 328-38.
12. Genzel Y., Vogel T., Buck J., Behrendt I., Ramirez D.V., Schiedner G., et al. High cell dencity cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014; 32(24): 2770-81.
13. Kolind M.P., Norby P.L., Flintegaard T.V., Berchtold M.W., Johnsen L.B. The B-domain of Factor VIII reduces cell membrane attachment to host cells under serum free conditions. J Biotechnol. 2010; 147(3-4): 198-204.
14. Rasmussen P.B. Method of producing proteins with FVIII activity and/or FVIII derivatives. Patent WO., № 1991000347 A1; 1991.
Рецензия
Для цитирования:
Морозов А.Н., Сидельников Г.Д., Емельянов И.М., Лапшин К.Е., Алимова Д.Р. Разработка процесса непрерывного культивирования клеток CHO - продуцентов рекомбинантного фактора свертываемости крови VIII. БИОпрепараты. Профилактика, диагностика, лечение. 2015;(4):26-31.
For citation:
Morozov A.N., Sidelnikov G.D., Emelyanov I.M., Lapshin K.E., Alimova D.R. Development of continuous cultivation of CHO cells producing recombinant blood coagulation factor VIII. BIOpreparations. Prevention, Diagnosis, Treatment. 2015;(4):26-31. (In Russ.)